Login to Your Account

Oncogenex Pharma drug fails in late-stage prostate cancer trial

By Michael Fitzhugh
Staff Writer

Monday, April 28, 2014

Oncogenex Pharmaceuticals Inc. shares (Nasdaq:OGXI) fell 60.3 percent after the company and its partner, Teva Pharmaceutical Industries Ltd., reported that their experimental prostate cancer therapy, custirsen, failed to perform better than standard chemotherapy in a pivotal trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription